DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,876 shares of the medical device company’s stock after selling 541 shares during the period. Kingswood Wealth Advisors LLC’s holdings in DexCom were worth $538,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. DSM Capital Partners LLC purchased a new stake in DexCom in the 4th quarter valued at $28,000. Valley National Advisers Inc. increased its position in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Riverview Trust Co acquired a new stake in DexCom during the first quarter worth about $32,000. MV Capital Management Inc. boosted its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the last quarter. Finally, Smithfield Trust Co boosted its holdings in DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 2.9 %

Shares of NASDAQ DXCM opened at $113.51 on Thursday. The stock has a market cap of $45.14 billion, a P/E ratio of 73.23, a PEG ratio of 2.69 and a beta of 1.22. The business’s fifty day simple moving average is $124.29 and its 200-day simple moving average is $125.85. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, equities analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,076 shares of company stock valued at $7,544,030. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DXCM. Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group upped their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $140.33.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.